When a lipid nanoparticle enters blood, interstitial fluid, or any biological medium, the interface between the synthetic lipid surface and the surrounding bioenvironment is rapidly remodeled by biomolecules. Within seconds, a layer of proteins, lipids, apolipoproteins, and small metabolites adsorbs onto the LNP surface, replacing the engineered surface with what biologists call the "biological identity" of the particle. This adsorbed layer, the protein corona, becomes the structure that cells, tissues, and immune receptors actually encounter, often bearing little resemblance to the carefully designed synthetic surface beneath it.
Corona formation is governed by the classical Vroman effect — high-abundance, low-affinity proteins (such as albumin) arrive first and are progressively replaced by lower-abundance, higher-affinity proteins (such as apolipoproteins and complement factors) over the first minutes to hours of exposure. For lipid nanoparticles, this dynamic exchange has profound implications because the particle surface is itself dynamic: PEG-lipids desorb on a predictable timescale (anchored by C14 acyl chains at >45% per hour; anchored by C18 dialkyl chains at only ~0.2% per hour), exposing fresh lipid surface for protein adsorption. The corona you characterize at 5 minutes is therefore not the corona your LNP presents at 2 hours, and both may differ substantially from the corona under continuous flow conditions that more closely mimic in vivo circulation. Understanding these kinetics is the foundation for designing LNPs whose surface properties remain stable and predictable after biological exposure.
Hard corona vs. soft corona: Mature corona research distinguishes two operationally defined populations. The hard corona comprises proteins bound with sufficiently high affinity and slow off-rates that they remain associated with the LNP through extensive washing and isolation; this population typically numbers 50-150 distinct proteins but only a handful at high abundance. The soft corona consists of loosely associated proteins that exchange rapidly with the surrounding medium; this population is biologically important because it can engage receptors during transit but is lost during most isolation workflows. Most functional consequences of corona formation are driven by a small subset of high-abundance hard-corona proteins (ApoE, ApoB, vitronectin, β2-glycoprotein I, albumin, complement C3, IgG) whose identity is determined primarily by LNP physicochemical properties rather than by the absolute composition of the medium.
Beyond proteins: Although the term "protein corona" emphasizes proteins, LNPs also recruit endogenous lipids (cholesteryl esters, phospholipids), apolipoprotein complexes (notably HDL particles that fully integrate with the LNP bilayer), and small metabolites. This expanded "biomolecular corona" can transfer endogenous lipids into the LNP bilayer and rearrange the lipid packing, modifying endosomal escape behavior and fusogenicity independently of any direct receptor engagement by adsorbed proteins. For lipid nanoparticles designed to release nucleic acid payloads into the cytoplasm, these non-protein components are increasingly recognized as important variables.
Corona composition is not random. The same physicochemical properties that define an LNP's synthetic identity — particle size, surface charge, PEG architecture, and lipid composition — together determine which proteins the LNP recruits and at what stoichiometry. Because these parameters are all tunable during formulation, corona engineering is, in principle, achievable for any defined target tissue or cell type. The four parameter classes below account for the great majority of corona variability observed across LNP studies.
Particle size influences the corona in two ways that act in opposite directions. Larger LNPs (80-120 nm) present a more gently curved surface that better accommodates large, multi-domain proteins such as ApoB-containing lipoproteins and complement components; this drives enrichment of lipophilic and opsonizing proteins. Smaller LNPs (30-60 nm) expose sharper curvature that sterically disfavors adsorption of large proteins and instead enriches smaller, more abundant species such as albumin and smaller apolipoproteins. The total surface area also scales with diameter, but for a given lipid mass, smaller particles contribute substantially more total surface for protein recruitment, intensifying the protein load per unit payload. Nanoparticle size analysis by dynamic light scattering and nanoparticle tracking analysis is therefore a prerequisite to any meaningful corona discussion.
Surface charge determines the sign and magnitude of electrostatic interaction with plasma proteins, the majority of which are negatively charged at physiological pH. Cationic LNPs (zeta potential >+15 mV) electrostatically attract anionic proteins and cluster opsonins such as complement C3 and immunoglobulins, driving macrophage clearance and dramatically shortening circulation time. Anionic LNPs (zeta potential below -20 mV) repel most proteins but recruit positively charged species and can still accumulate vitronectin or β2-glycoprotein I through non-electrostatic interactions. Near-neutral LNPs (zeta potential between -10 and +10 mV) recruit a more physiological mixture dominated by apolipoproteins; this range is also where ionizable lipids sit at physiological pH, which is one reason ionizable lipid nanoparticles display reproducible biodistribution profiles across labs. Nanoparticle surface charge analysis and LNP zeta potential optimization services are commonly used to position a formulation within the desired window.
PEGylation is the single most important lever for corona engineering. PEG creates a hydrated steric barrier whose density (mol% of total lipid) and brush thickness (PEG molecular weight) determine the residual protein adsorption after PEG shedding. Below ~0.5 mol% PEG, LNPs acquire a near-complete protein corona within minutes; at 1.5-2.5 mol% the corona is delayed and quantitatively reduced; above 5 mol% the corona is sparse but cellular uptake may be impaired. The PEG-lipid anchor controls shedding kinetics and therefore the time at which corona formation begins in earnest: C14 anchors release quickly, allowing protein adsorption during circulation; C18 anchors persist much longer, providing true stealth behavior. LNP PEG-lipid optimization services systematically screen these variables to balance stealth with eventual functional delivery.
Beyond the ionizable lipid and the PEG-lipid, the helper lipids (phosphatidylcholine, phosphatidylethanolamine, cholesterol) leave their fingerprints on the corona. Helper lipids modulate bilayer rigidity, phase behavior, and fusogenicity, all of which influence which proteins can stably integrate into the surface. DSPC-containing LNPs accumulate preferentially in the spleen; DOPE-containing LNPs route to the liver through differential ApoE recruitment. Auxiliary charged lipids can be incorporated to alter LNP surface properties and influence endogenous protein recruitment. deliberately shift surface charge and bias the corona toward vitronectin (for lung targeting) or β2-glycoprotein I (for spleen targeting). For each new indication, LNP lipid ratio optimization services and LNP helper lipid optimization services can identify the composition that yields the most useful corona for a chosen application.
Table 1. Physicochemical Drivers of LNP Protein Corona Composition.
| Parameter | Range | Corona Tendency | Functional Consequence |
| Particle Size | 30-120 nm | Small (30-60 nm): albumin, ApoA-I enriched; Large (80-120 nm): ApoB, complement enriched | Directs biodistribution and clearance rate |
| Zeta Potential | -20 to +30 mV | Cationic: complement + IgG; Anionic: vitronectin, β2-GPI; Near-neutral: ApoE balanced | Modifies MPS clearance and ApoE-LDLR axis |
| PEG Density | 0-5 mol% | Low: full corona; Mid (1.5-2.5%): delayed corona; High (>5%): sparse corona but low uptake | Sets stealth duration before functionalization |
| PEG Anchor | C14 vs. C18 | C14: rapid shedding, fast corona acquisition; C18: sustained shielding, delayed corona | Determines when corona forms during circulation |
| Helper Lipid | DSPC / DOPE / Cholesterol | DOPE favors ApoE recruitment; DSPC biases toward spleen accumulation | Modifies tissue tropism via corona-mediated recognition |
| Auxiliary Charged Lipid | Cationic / Anionic / Ionizable | Cationic (DOTAP): vitronectin-rich lung; Anionic (18-PA): β2-GPI-rich spleen | Engineered corona for extrahepatic delivery |
BOC Sciences supports formulation-side corona engineering — tune PEG density, anchor type, helper lipid, and surface charge with predictive proteomic feedback.
The corona is not an inconvenience to be eliminated; it is the operational interface of the LNP in any biological setting. Every aspect of performance — colloidal stability in serum, cellular uptake pathway, intracellular fate, biodistribution, target engagement, payload release — is mediated or modulated by the adsorbed layer. The most consequential effects are summarized below.
Protein adsorption is rarely aggregation-neutral. Adsorbed proteins can bridge multiple LNPs through multivalent binding, producing aggregates that grow from sub-100 nm primary particles to micrometer-sized clusters within minutes of serum exposure. For systems engineered to be near-neutral (zeta potential -10 to +5 mV), bridging is dominated by specific protein-protein interactions rather than electrostatic attraction, and the rate of aggregation depends sensitively on the relative concentrations and binding kinetics of opsonins and dysopsonins. Even non-aggregating LNPs experience measurable size increases of 5-20 nm following corona formation, a shift that is biologically meaningful because it pushes particles out of the optimal size window for lymphatic drainage or LDL-receptor-mediated uptake.
The corona provides the molecular handles that cells use to recognize and internalize LNPs. The most widely studied of these is ApoE, which binds the LNP surface through its amphipathic helices and presents the receptor-binding domain to LDLR, LR1, and related receptors on hepatocytes and other ApoE-receptive cells. Multiple other proteins — ApoB, ApoA-I, vitronectin, β2-glycoprotein I, complement C3, transferrin — engage distinct receptors and bias uptake into different cell populations. For formulations intended to be taken up broadly by antigen-presenting cells, the corona profile that maximizes albumin plus complement C3 is desirable; for formulations intended to reach hepatocytes, the corona profile that maximizes ApoE is desirable. These two outcomes require almost opposite LNP designs.
Once internalized, the corona continues to influence intracellular fate. Adsorbed proteins can engage endosomal receptors that sort the LNP toward recycling, degradation, or transcytosis; can recruit signaling proteins that modify membrane trafficking; and can shield or expose fusogenic epitopes on the LNP bilayer that determine endosomal escape efficiency. A corona dominated by vitronectin, for example, has been associated with αvβ3 integrin engagement and routing toward macropinocytosis, while ApoE-enriched coronas typically traffic through LDLR-dependent clathrin-mediated uptake and exhibit more efficient endosomal escape. Nanoparticle intracellular localization detection by confocal co-localization with LAMP1, Rab5, Rab7, and galectin-8 is the standard experimental tool for connecting corona composition to intracellular outcome.
No corona component has been more thoroughly characterized for LNPs than apolipoprotein E. PEG shedding, ionizable-lipid protonation, and the absence of competing cationic surface charge together promote ApoE binding, which in turn drives recognition by LDLR and delivery to hepatocytes. ApoE association can promote LDLR-mediated recognition and is an important mechanism contributing to hepatic uptake of systemically administered LNPs. Liver de-targeting — a prerequisite for LNPs aimed at tumors, lung, spleen, brain, or immune cells — is therefore equivalent to corona engineering to reduce ApoE and β2-GPI while enriching alternative corona species such as albumin, vitronectin, or intentionally pre-coated proteins. Liver-targeted LNP development services and targeted LNP development at BOC Sciences are designed around this principle.
Active targeting ligands (antibodies, peptides, aptamers, glycans) are usually displayed at sub-stoichiometric surface densities, where even a thin protein corona can fully mask them. Mannose-conjugated LNPs, for example, lose measurable CD206 engagement when albumin adsorption is high; anti-CD40 antibody fragments suffer similar attenuation. The corona can also produce unintended new "ligands" by exposing Fc-binding regions of adsorbed IgG, an effect that redirects the LNP to FcγR-bearing macrophages regardless of the displayed targeting moiety. Designing coronas that preserve targeting-ligand accessibility — through spacer engineering, ligand pre-coating, or corona-resistant anchor chemistries — is an active area of method development.
Corona adsorption changes bilayer packing and surface tension at the LNP-water interface, both of which influence payload retention. mRNA-LNPs that are stable in buffered saline can lose 20-40% of encapsulated cargo upon 2-hour incubation in 50% human serum, driven in part by the lipid-remodeling effects of HDL integration and the fusogenic effects of complement insertion. Detailed strategies for managing this loss are reviewed in our resource on LNP payload retention during serum exposure; the practical lever is again PEG density and helper-lipid selection, both of which shape the corona and the bilayer simultaneously.
Corona characterization is more demanding than conventional LNP characterization because the analyte is itself dynamic and present in vast excess over the LNP. Three experimental pillars support the field: isolation of the LNP-corona complex from free plasma proteins; identification and quantification of the adsorbed proteins; and functional readouts that connect corona composition to biological outcome.
The classical method for corona isolation is centrifugation through a sucrose cushion at 100,000-200,000 × g, which pellets LNP-corona complexes while leaving free proteins in the supernatant. The pellet is washed multiple times to remove loosely bound soft-corona species, then subjected to proteomic analysis. Size-exclusion chromatography using agarose-based SEC media is an important alternative for larger or more fragile LNPs that pellet poorly; SEC preserves soft-corona populations more faithfully because there is no high-g shear. Affinity capture using biotinylated or magnetic beads, or pull-down with antibodies against LNP components, can further enhance specificity but at the cost of possibly perturbing the corona during capture. The choice of method strongly affects which proteins are detected; cross-method validation is now considered essential. Nanoparticle structural characterization and nanoparticle morphology characterization provide complementary size and shape data before and after corona isolation.
Isolated corona proteins are denatured, reduced, alkylated, and digested with trypsin or Lys-C; the resulting peptides are analyzed by liquid chromatography coupled to tandem mass spectrometry. Data-dependent acquisition provides protein identification, while label-free quantification (intensity-based or spectral counting) provides relative abundance across samples. More recent workflows use data-independent acquisition or multiplexed isobaric labeling for multiplexed comparison of corona profiles across formulation variants in a single run. Bioinformatics processing against species-specific plasma proteomes identifies statistically significant enrichment or depletion relative to the input plasma, a key step because most detected proteins are simply the most abundant plasma species regardless of any LNP-specific binding.
A proteomic profile is meaningful only insofar as it predicts biological behavior. The most informative functional readouts are (i) cellular association assays in cell lines or primary cells expressing candidate corona receptors, using fluorescent or radiolabeled LNPs; (ii) targeted gene-expression or silencing assays that confirm functional delivery downstream of uptake; (iii) nanoparticle in vivo distribution analysis that links corona composition to organ-level accumulation; and (iv) immune phenotyping that detects opsonin-driven complement or Fc-receptor engagement. Combining these readouts in a multivariate model is the basis of the emerging discipline of "corona fingerprinting," which has been shown to outperform particle size, charge, or PEG density alone in predicting cell-type tropism.
Table 2. Comparison of LNP Protein Corona Characterization Methods.
| Method | Principle | Strengths | Limitations | Best Application |
| Ultracentrifugation | Pellet LNP-corona at 100,000-200,000 × g through sucrose cushion | Simple; broadly applicable; preserves hard corona | Loses soft corona; high g shear can perturb adsorption | Routine hard-corona profiling of robust LNPs |
| Size-Exclusion Chromatography (SEC) | Separate LNP-corona from free protein by size | Soft-corona preserved; native state maintained | Lower recovery; column-LNP interactions possible | Fragile LNPs and soft-corona studies |
| Magnetic Bead Affinity Capture | Affinity-tagged LNP pulled by magnetic beads | High specificity; works with low LNP amounts | Capture chemistry may perturb corona | Low-concentration samples; tagged LNPs |
| LC-MS/MS (DDA / DIA / Isobaric Labeling) | Proteolytic digestion and mass spectrometry | High sensitivity; quantitative; hundreds of proteins | Workflow-intensive; sensitive to contamination | Comprehensive corona fingerprinting |
| Label-Free Quantification | Ion intensity or spectral counting across samples | No labeling; multiplex comparison | Requires strict run-to-run reproducibility | Comparing corona across formulation variants |
| Cellular Association Assay | Quantify uptake in receptor-expressing cells | Direct functional readout; receptor-specific | Does not give protein-level mechanism | Validating corona-receptor hypothesis |
BOC Sciences combines LNP isolation, LC-MS/MS proteomics, and cell-based uptake assays to convert corona composition into actionable biodistribution insight.
Corona control strategies fall into two broad camps: those that suppress corona formation altogether, and those that exploit corona formation as a design feature. The first approach is essentially "stealth engineering." The second is "corona programming," and it is where the most recent gains in extrahepatic delivery have come from. In practice, every successful LNP formulation combines elements of both.
PEG is the workhorse stealth polymer for LNPs, but its limitations — anti-PEG immunogenicity, dose-dependent accelerated blood clearance, and incomplete corona suppression — have motivated alternatives. Pegylated lipid nanoparticles remain the standard of comparison, but alternative zwitterionic polymers (poly(carboxybetaine), poly(sulfobetaine)), hydrophilic polysarcosine, and poly(2-oxazoline) coatings can produce lower-fouling surfaces in side-by-side studies and avoid anti-PEG IgM responses on repeat dosing. The trade-off is synthetic complexity: each alternative requires its own lipid anchor, quantified shedding rate, and corona-validation workflow. LNP excipient screening services at BOC Sciences include head-to-head comparison of PEG and PEG alternatives for both corona suppression and payload retention.
Targeting ligands must remain accessible above the corona. Three design levers are commonly used. First, ligand-PEG-lipid spacer length should exceed the predicted corona thickness: 2-3 kDa PEG spacers are needed for antibody fragments; 1-2 kDa PEG spacers suffice for small peptides and glycans. Second, ligand density should be sufficient to overcome burial without being so high that it destabilizes the bilayer; 2-5 mol% is a common workable window. Third, the ligand itself should be chosen for compatibility with the corona — some peptides retain activity when co-adsorbed with albumin; others lose binding in crowded surface conditions. Nanoparticle conjugation services and nanoparticle functionalization services at BOC Sciences support systematic titration of ligand density with corona-aware assay feedback.
Pre-coating bypasses corona heterogeneity by deliberately installing the desired biomolecular layer before in vivo exposure. Custom synthesis of corona-engineering proteins and peptides is available from BOC Sciences: a mutant apolipoprotein that binds lipids but cannot engage LDLR, which saturates the LNP surface and blocks subsequent wild-type ApoE recruitment. Analogous strategies have been reported with engineered albumin variants, designer annexins, and recombinant vitronectin variants. Pre-coating is intrinsically reproducible because it removes the dependence on the unknown plasma composition of each individual, but it requires well-characterized protein preparation and careful batch-to-batch consistency assessment. Custom synthesis of corona-engineering proteins and peptides is available from BOC Sciences for research-stage projects.
Rather than installing a single protein of choice, glycoengineering and apolipoprotein recruitment tuning aim to bias the natural corona composition toward a desired profile. Display of branched oligomannose structures, for example, mimics pathogen surfaces and enriches mannose-binding lectins; display of sialic acid caps reduces complement activation; incorporation of cholesterol-binding peptides enriches HDL components. For apolipoprotein tuning, the most powerful lever remains auxiliary lipid chemistry: ionizable lipids with subtle head-group or tail-length modifications shift ApoE-vs-other apolipoprotein balance reproducibly without major changes in size or charge. Optimization of these variables falls within the scope of LNP ionizable lipid optimization services.
Storage conditions profoundly affect how the corona behaves on first biological contact. LNPs formulated at low ionic strength and slightly acidic pH (5.5-6.5) display different surface-charge signatures than the same LNPs after storage in physiological saline at pH 7.4; lyophilization with appropriate cryoprotectants preserves the engineered surface better than repeated freeze-thaw cycles. Buffer composition, sucrose or trehalose content, and residual ethanol all influence the initial bilayer organization and therefore the early steps of corona formation upon dilution into plasma. LNP buffer screening services and LNP cryoprotectant screening services can be deployed to stabilize both the formulation and its eventual corona profile.
Table 3. Engineering Strategies for Controlling the LNP Protein Corona.
| Engineering Strategy | Mechanism | Effect on Corona | Best Use Case |
| PEG / PEG-Alternative Density | Hydrated steric barrier | Delays and reduces overall corona adsorption | General stealth for hepatic and non-hepatic LNPs |
| PEG-Lipid Anchor Type | Sets shedding kinetics (C14 fast / C18 slow) | Controls timing of corona onset during circulation | Tuning functional delivery window |
| Ligand-PEG Spacer Length | Positions ligand above expected corona thickness | Preserves active targeting amid corona | Antibody, peptide, glycan display |
| Pre-Coating (dApoE, Albumin Variants) | Installs engineered biomolecular layer ex vivo | Bypasses patient-to-patient corona variability | Liver de-targeting, reproducible tropism |
| SORT Auxiliary Lipid | Permanent surface charge from a fifth lipid | Selectively enriches vitronectin, β2-GPI, or albumin | Lung, spleen, immune-cell targeting |
| Helper Lipid Selection | Modulates bilayer packing and fusogenicity | Differential apolipoprotein recruitment | Fine-tuning ApoE vs. albumin balance |
| Lyophilization with Cryoprotectant | Preserves bilayer organization in storage | Consistent initial surface at first plasma contact | Long-term storage; batch-to-batch reproducibility |
BOC Sciences engineers lipid composition, PEG architecture, and surface functionalization to deliver LNPs whose corona profile matches a chosen biodistribution goal.
Problem: The LNP remains stable in formulation buffer but shows rapid size growth, high PDI, particle loss, or visible aggregation after serum or plasma exposure.
Likely causes: insufficient steric shielding, high exposed charge or hydrophobicity, unstable PEG presentation, or protein-mediated particle bridging.
Optimization strategy: compare PEG density and anchor type, reduce extreme surface charge, screen helper lipid and cholesterol ratios, and verify that buffer conditions do not pre-destabilize the LNP. Evaluate particle recovery and payload retention together with DLS so that protein association is not confused with irreversible aggregation.
Problem: Flow cytometry or microscopy shows strong LNP association with cells, yet reporter expression, gene modulation, or another payload-specific response remains weak.
Likely causes: corona-mediated uptake through a nonproductive receptor pathway, greater trafficking to lysosomes, or reduced endosomal membrane interaction after protein association.
Optimization strategy: combine uptake with intracellular localization and functional readouts, then modify ionizable lipid, helper lipid, PEG shedding, or surface chemistry. LNP transfection troubleshooting is most informative when the uptake-to-function gap is investigated as a trafficking problem rather than simply increasing dose.
Problem: A formulation designed for another tissue still shows dominant hepatic accumulation.
Likely causes: surface exposure after PEG shedding and a lipid composition that favors ApoE or other lipoprotein association, followed by receptor-mediated liver uptake.
Optimization strategy: compare corona proteomics across formulations and test whether changes in ionizable lipid, helper lipid, PEG-lipid, charge, or glycan presentation reduce ApoE enrichment while preserving stability. For projects intentionally using hepatic delivery, liver-targeted LNP development can instead use this endogenous pathway as part of the design strategy.
Problem: A ligand-functionalized LNP binds its target receptor in buffer but loses selectivity in serum-containing assays.
Likely causes: protein masking, insufficient ligand extension beyond the corona, ligand reorientation, or excessive nonspecific uptake driven by newly recruited proteins.
Optimization strategy: vary spacer length, ligand density, PEG background, and conjugation orientation; then repeat receptor-binding and cell-uptake testing after standardized biofluid preincubation. Active targeting should be considered validated only when receptor-dependent recognition is retained under the biological exposure conditions relevant to the project.
Table 4. Troubleshooting Matrix for Common LNP Protein Corona Problems.
| Problem | First Check | Second Check | Optimization Direction |
| Serum aggregation | Size/PDI and particle recovery | PEG presentation and surface charge | Shielding, lipid packing, buffer conditions |
| High uptake, low function | Cellular internalization | Endosomal/lysosomal localization | Trafficking and endosomal escape design |
| Unexpected liver accumulation | ApoE and apolipoprotein enrichment | PEG shedding and lipid composition | Surface chemistry and endogenous protein recruitment |
| Loss of active targeting | Ligand accessibility after serum exposure | Nonspecific corona-mediated uptake | Spacer, ligand density, and shielding architecture |
BOC Sciences provides systematic corona-focused troubleshooting — from proteomic diagnosis to redesigned PEG-lipid, helper lipid, and ligand architectures.
Effective corona control requires the integration of three capabilities: precise LNP formulation at small and intermediate scales, quantitative proteomic characterization of the resulting corona, and functional validation that links corona composition to biological outcome. BOC Sciences provides all three within a coordinated service framework, enabling corona hypothesis testing and corona engineering with iterative feedback in days rather than months.
BOC Sciences delivers complete corona workflows: ex vivo incubation of formulated LNPs in human, primate, or rodent plasma (or in defined protein cocktails for mechanism studies), isolation of LNP-corona complexes by centrifugation or SEC, and LC-MS/MS-based identification with label-free quantification. Each project includes a defined protein database, statistical filtering for LNP-enriched proteins, and a clear comparison against input plasma composition. Output includes ranked corona protein lists with abundance scores, hierarchical clustering across formulations, and optional Western blot validation of high-priority candidates. Combined with nanoparticle cellular uptake testing and nanoparticle in vivo imaging services, corona profiles can be definitively linked to cell-type and organ-level outcomes.
BOC Sciences supports corona engineering through formulation revision based on proteomic feedback. Concretely, this includes LNP PEG-lipid optimization (chain length, anchor type, density titration), LNP lipid ratio optimization (ionizable : helper : cholesterol : PEG ratios), LNP helper lipid optimization (DSPC vs. DOPE vs. sphingomyelin), LNP cholesterol optimization, and LNP ionizable lipid optimization across BOC Sciences' in-house ionizable lipid library. For non-hepatic targeting, complementary nanoparticle surface functionalization workflows add targeting ligands under corona-aware design constraints. LNP process optimization and microfluidic LNP production services ensure the engineered surface is preserved reproducibly at scale. The integrated workflow supports projects from custom synthesis of novel lipids through to comprehensive biodistribution validation.
Table 5. BOC Sciences Services for Protein Corona Research and LNP Engineering.
| Service | Scope | Key Deliverables | Inquiry |
| LNP Protein Corona Isolation | Centrifugation- and SEC-based isolation from human, primate, or rodent plasma; defined cocktail comparison | Isolated LNP-corona complexes; QC of integrity and recovery | Inquiry |
| LNP Corona LC-MS/MS Profiling | Trypsin digestion, label-free quantification, statistical enrichment vs. plasma | Protein list with abundance scores; corona fingerprint across formulations | Inquiry |
| LNP PEG-Lipid Optimization | Chain length, anchor type, density titration; shedding rate analysis | Optimized PEG-lipid architecture; corona timing data | Inquiry |
| LNP Ionizable Lipid Optimization | Screening of 50-200+ ionizable lipids; pKa and endosomal escape evaluation | Ranked lipid candidates with corona-relevant properties | Inquiry |
| LNP Helper Lipid and Cholesterol Optimization | DSPC vs. DOPE vs. sphingomyelin screen; cholesterol loading optimization | Tuned bilayer with desired bilayer-ApoE interaction | Inquiry |
| LNP Corona Functional Validation | Cellular uptake, endosomal escape, and biodistribution assays linked to corona composition | Functional biodistribution and uptake data correlated with corona profile | Inquiry |
| LNP In Vivo Biodistribution Analysis | Quantitative tissue biodistribution in rodent models with IVIS or radiolabel quantitation | Biodistribution report across organs; corona-organ correlation analysis | Inquiry |
The protein corona is the operational reality of every lipid nanoparticle in biological systems. Surface properties — particle size, zeta potential, PEG density and architecture, helper lipid composition — collectively determine which biomolecules associate with the LNP, and that adsorbed layer in turn governs colloidal stability, cellular uptake pathway, intracellular trafficking, biodistribution, and ligand accessibility. The most consequential corona component for current LNP therapeutics is ApoE, whose LDLR-mediated recognition establishes the liver as the default destination; expanding LNP reach to extrahepatic tissues is therefore equivalent to controlling ApoE recruitment and redirecting the corona toward albumin, vitronectin, β2-glycoprotein I, or deliberately pre-coated proteins. Systematic corona engineering requires three coordinated capabilities — controllable formulation (PEG, ionizable lipid, helper lipid, ligand density), quantitative proteomic readout (isolation + LC-MS/MS), and functional validation (cell-based and in vivo biodistribution) — which BOC Sciences provides as an integrated service. With these capabilities, research teams can move from descriptive corona analysis to predictive corona design, building LNPs whose biological identity is as deliberately engineered as their synthetic one.
